International Association for the Study of Lung Cancer

05/28/2026

Women in thoracic oncology: your voice matters.

The IASLC Women in Thoracic Oncology Task Force invites you to participate in a brief survey focused on the experiences, challenges, and opportunities of individuals who identify as women in thoracic oncology.

Your feedback will help guide future IASLC initiatives, programs, and actions aimed at advancing equity across the field.

Thank you for helping shape a more inclusive future for the global thoracic oncology community.

Take the survey: https://bit.ly/4uAPNwd

05/27/2026

📰 ICYMI: Inhaled gene therapy receives FDA RMAT designation for advanced NSCLC.

The decision was based on findings from the KYANITE-1 trial, which demonstrated that the treatment was generally well tolerated with single-agent antitumor activity observed.

Read the details in ILCN:

The decision was based on findings from the KYANITE-1 trial, which demonstrated that the treatment was generally well tolerated with single-agent antitumor activity observed.

05/27/2026

Hear from IASLC 2026 Hot Topic Chair Fabrizio Bianchi on what to expect at this year’s meeting in Dublin. From exploring the mechanisms of primary and acquired immunotherapy resistance, tumor-immune interactions, the tumor microenvironment to emerging biomarkers and therapies this meeting is not one to miss! Learn more about this year’s Hot Topic Meeting and register in the link in our bio.

05/24/2026

🌱 Drs. Joan H. Schiller and Roselle de Guzman say championing public policies that prioritize clean air and incorporating environmental exposure histories into clinical care are the future of the field.

Learn more in ILCN:

Drs. Joan H. Schiller and Roselle de Guzman say championing public policies that prioritize clean air and incorporate environmental exposure histories into clinical care are the future of the field.

05/21/2026

🧬 Dr. Yongfeng He said recent data show EGFR-L858R to be a shared, druggable neoantigen and provide a compelling rationale for the development of mutation-directed immunotherapies.

Read his insights in ILCN:

Dr. Yongfeng He said recent data show EGFR-L858R to be a shared, druggable neoantigen and provide a compelling rationale for the development of mutation-directed immunotherapies.

05/20/2026

Available now! New microlearning and printable resource for thoracic oncology care teams.

As BiTE therapies continue to emerge in lung cancer treatment, early recognition and management of cytokine release syndrome (CRS) is critical.

This quick guide for nurses, APPs, and multidisciplinary clinical care teams includes:
✔ Common signs and symptoms of CRS
✔ Management considerations and supportive care strategies
✔ A practical, step-by-step patient care workflow for early recognition and response

Designed to support confident, coordinated care in real-world clinical settings, this printable resource can be shared across your institution and care teams.

Access and share the resource: https://bit.ly/4tzGxXT

Are you a nurse or allied health professional working in thoracic oncology? Help shape future IASLC education and resources by participating in the NAHP survey: https://bit.ly/48StXvh

05/19/2026

In this episode of Lung Cancer Considered, Dr. Narjust Florez, Natalie Brown, and Dr. Aurora Lucas discuss how patients and caregivers are using artificial intelligence to better understand care, navigate information, and communicate with healthcare teams, while also addressing the risks of misinformation and overreliance.

🎧 Listen here: https://bit.ly/4nz2gO0

05/18/2026

Citing data from the FPG500 program, Drs. Antonio Vitale and Emilio Bria write that integrating genome profiling and molecular tumor boards into daily practice is feasible and yields measurable survival benefits for patients with actionable molecular alterations.

🔗 Read more in ILCN:

Citing data from the FPG500 program, Drs. Antonio Vitale and Emilio Bria write that integrating genome profiling and molecular tumor boards into daily practice is feasible and yields measurable survival benefits for patients with actionable molecular alterations.

05/16/2026

The full program for the IASLC World Conference on Lung Cancer 2026 is now live! 🌏

Join us in Seoul from September 12–15 for four days of groundbreaking science, collaboration, and connection with the global thoracic oncology community.

WCLC 2026 begins Saturday with a full day of interactive sessions, including:
✔ Debates
✔ Career-focused discussions
✔ Joint programming
✔ CT Screening & Early Detection Workshop (ticketed)

⏰ Early bird registration is still available
🏨 Hotel rooms are limited — secure yours early
💡 IASLC members receive additional savings

Start planning your schedule and register today: https://bit.ly/4eIYgs0

05/15/2026

Researchers, clinicians, and early-career investigators across Latin America and beyond this is your opportunity to put your work on an international stage.

Abstract submissions are still open!

Join a multidisciplinary community advancing thoracic oncology through collaboration, innovation, and shared expertise. Whether your work focuses on translational science, clinical research, screening, biomarkers, or patient care, we encourage you to submit.

Why submit?
✔ Share your research with global experts
✔ Contribute to conversations shaping lung cancer care
✔ Build connections across the region and beyond
✔ Be part of the next generation of progress in thoracic oncology

Submit your abstract today: https://bit.ly/3PtViNH